Top

BMC Gastroenterology

Published in:

Open Access 01-12-2023 | Fatty Liver | Research

Correlation between nonalcoholic fatty liver disease and left ventricular diastolic dysfunction in non-obese adults: a cross-sectional study

Authors: Fangyuan Cong, Luying Zhu, Lihua Deng, Qian Xue, Jingtong Wang

Published in: BMC Gastroenterology | Issue 1/2023

Abstract

Background and aims

Non-alcoholic fatty liver disease (NAFLD) is associated with a greater risk of developing cardiovascular disease and have adverse impacts on the cardiac structure and function. Little is known about the effect of non-obese NAFLD upon cardiac function. We aimed to compare the echocardiographic parameters of left ventricle (LV) between non-obese NAFLD group and control group, and explore the correlation of non-obese NAFLD with LV diastolic dysfunction.

Methods and results

In this cross-sectional study, 316 non-obese inpatients were enrolled, including 72 participants with NAFLD (non-obese NAFLD group) and 244 participants without NAFLD (control group). LV structural and functional indices of two groups were comparatively analyzed. LV diastolic disfunction was diagnosed and graded using the ratio of the peak velocity of the early filling (E) wave to the atrial contraction (A) wave and E value. Compared with control group, the non-obese NAFLD group had the lower E/A〔(0.80 ± 0.22) vs (0.88 ± 0.35), t = 2.528, p = 0.012〕and the smaller LV end-diastolic diameter〔(4.51 ± 0.42)cm vs (4.64 ± 0.43)cm, t = 2.182, p = 0.030〕. And the non-obese NAFLD group had a higher prevalence of E/A < 1 than control group (83.3% vs 68.9%, X² = 5.802, p = 0.016) while two groups had similar proportions of LV diastolic dysfunction (58.3% vs 53.7%, X² = 0.484, p = 0.487). Multivariate logistic regression analysis showed that non-obese NAFLD was associated with an increase in E/A < 1 (OR = 6.562, 95%CI 2.014, 21.373, p = 0.002).

Conclusions

Non-obese NAFLD was associated with decrease of E/A, while more research will be necessary to evaluate risk of non-obese NAFLD for LV diastolic dysfunction in future.

Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005–23. https://doi.org/10.1002/hep.25762.CrossRefPubMed

Younossi ZM. Non-alcoholic fatty liver disease - A global public health perspective. J Hepatol. 2019;70:531–44. https://doi.org/10.1016/j.jhep.2018.10.033.CrossRefPubMed

Zhou F, Zhou J, Wang W, et al. Unexpected Rapid Increase in the Burden of NAFLD in China From 2008 to 2018: A Systematic Review and Meta-Analysis. Hepatology. 2019;70:1119–33. https://doi.org/10.1002/hep.30702.CrossRefPubMed

Estes C, Anstee QM, Arias-Loste MT, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. J Hepatol. 2018;69:896–904. https://doi.org/10.1016/j.jhep.2018.05.036.CrossRefPubMed

Ye Q, Zou B, Yeo YH, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5:739–52. https://doi.org/10.1016/s2468-1253(20)30077-7.CrossRefPubMed

Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004,363:157–163. https://doi.org/10.1016/s0140-6736(03)15268-3

Eslam M, Fan JG, Mendez-Sanchez N. Non-alcoholic fatty liver disease in non-obese individuals: the impact of metabolic health. Lancet Gastroenterol Hepatol. 2020;5:713–5. https://doi.org/10.1016/s2468-1253(20)30090-x.CrossRefPubMed

Kam L, Huang DQ, Teng MLP, et al. Clinical profiles of Asians with NAFLD: A systematic review and meta-analysis. Dig Dis. 2021. https://doi.org/10.1159/000521662.CrossRefPubMed

10.

Niriella MA, Kasturiratne A, Pathmeswaran A, et al. Lean non-alcoholic fatty liver disease (lean NAFLD): characteristics, metabolic outcomes and risk factors from a 7-year prospective, community cohort study from Sri Lanka. Hepatol Int. 2019;13:314–22. https://doi.org/10.1007/s12072-018-9916-4.CrossRefPubMed

11.

Singh SP, Kar SK, Panigrahi MK, et al. Profile of patients with incidentally detected nonalcoholic fatty liver disease (IDNAFLD) in coastal eastern India. Trop Gastroenterol. 2013;34:144–52. https://doi.org/10.7869/tg.118.CrossRefPubMed

12.

Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. J Hepatol. 2017;67:862–73. https://doi.org/10.1016/j.jhep.2017.06.003.CrossRefPubMed

13.

Feng RN, Du SS, Wang C, et al. Lean-non-alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population. World J Gastroenterol. 2014;20:17932–40. https://doi.org/10.3748/wjg.v20.i47.17932.CrossRefPubMedPubMedCentral

14.

Nakatsuka T, Tateishi R, Koike K. Changing clinical management of NAFLD in Asia. Liver Int. 2021. https://doi.org/10.1111/liv.15046.CrossRefPubMed

15.

Kuchay MS, Martínez-Montoro JI, Choudhary NS, et al. Non-Alcoholic Fatty Liver Disease in Lean and Non-Obese Individuals: Current and Future Challenges. Biomedicines. 2021;9:1346. https://doi.org/10.3390/biomedicines9101346.CrossRefPubMedPubMedCentral

16.

Ha Y, Seo N, Shim JH, et al. Intimate association of visceral obesity with non-alcoholic fatty liver disease in healthy Asians: A case-control study. J Gastroenterol Hepatol. 2015;30:1666–72. https://doi.org/10.1111/jgh.12996.CrossRefPubMed

17.

Zou ZY, Wong VW, Fan JG. Epidemiology of nonalcoholic fatty liver disease in non-obese populations: Meta-analytic assessment of its prevalence, genetic, metabolic, and histological profiles. J Dig Dis. 2020;21:372–84. https://doi.org/10.1111/1751-2980.12871.CrossRefPubMed

18.

Hallsworth K, Hollingsworth KG, Thoma C, et al. Cardiac structure and function are altered in adults with non-alcoholic fatty liver disease. J Hepatol. 2013;58:757–62. https://doi.org/10.1016/j.jhep.2012.11.015.CrossRefPubMed

19.

Sunbul M, Kivrak T, Durmus E, et al. Nonalcoholic Steatohepatitis Score is an Independent Predictor of Right Ventricular Dysfunction in Patients with Nonalcoholic Fatty Liver Disease. Cardiovasc Ther. 2015;33:294–9. https://doi.org/10.1111/1755-5922.12145.CrossRefPubMed

20.

Li X, Heiskanen JS, Ma H, et al. Fatty liver index and left ventricular mass: prospective associations from two independent cohorts. J Hypertens. 2021;39:961–9. https://doi.org/10.1097/hjh.0000000000002716.CrossRefPubMed

21.

Lee YH, Kim KJ, Yoo ME, et al. Association of non-alcoholic steatohepatitis with subclinical myocardial dysfunction in non-cirrhotic patients. J Hepatol. 2018;68:764–72. https://doi.org/10.1016/j.jhep.2017.11.023.CrossRefPubMed

22.

Lee M, Kim KJ, Chung TH, et al. Nonalcoholic fatty liver disease, diastolic dysfunction, and impaired myocardial glucose uptake in patients with type 2 diabetes. Diabetes Obes Metab. 2021;23:1041–51. https://doi.org/10.1111/dom.14310.CrossRefPubMed

23.

Chung GE, Lee JH, Lee H, et al. Nonalcoholic fatty liver disease and advanced fibrosis are associated with left ventricular diastolic dysfunction. Atherosclerosis. 2018;272:137–44. https://doi.org/10.1016/j.atherosclerosis.2018.03.027.CrossRefPubMed

24.

Guidelines of prevention and treatment for nonalcoholic fatty liver disease:a 2018 update. J Pract Hepatol. 2018,21:177–186.doi:https://doi.org/10.3969/j.issn.1672-5069.2018.02.007

25.

Guidelines for management of nonalcoholic fatty liver disease:an updated and revised edition. Chin J Hepatol. 2010,18:163–166.doi:https://doi.org/10.3760/cma.j.issn.1007-3418.2010.03.002

26.

Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12. https://doi.org/10.7326/0003-4819-150-9-200905050-00006.CrossRefPubMedPubMedCentral

27.

Hu YM, Wu XL, Hu ZH, et al. Study of formula for calculating body surface areas of the Chinese adults. Acta Physiol Sin. 1999;51:45–8. https://doi.org/10.3321/j.issn:0371-0874.1999.01.008.CrossRef

28.

Silbiger JJ. Pathophysiology and Echocardiographic Diagnosis of Left Ventricular Diastolic Dysfunction. J Am Soc Echocardiogr. 2019;32:216-232.e212. https://doi.org/10.1016/j.echo.2018.11.011.CrossRefPubMed

29.

Shida T, Oshida N, Suzuki H, et al. Clinical and anthropometric characteristics of non-obese non-alcoholic fatty liver disease subjects in Japan. Hepatol Res. 2020;50:1032–46. https://doi.org/10.1111/hepr.13543.CrossRefPubMed

30.

Flegal KM, Kit BK, Orpana H, et al. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA. 2013;309:71–82. https://doi.org/10.1001/jama.2012.113905.CrossRefPubMedPubMedCentral

31.

Li Y, Chen Y, Tian X, et al. Comparison of Clinical Characteristics Between Obese and Non-Obese Patients with Nonalcoholic Fatty Liver Disease (NAFLD). Diabetes Metab Syndr Obes. 2021;14:2029–39. https://doi.org/10.2147/dmso.S304634.CrossRefPubMedPubMedCentral

32.

Wong VW, Wong GL, Chan RS, et al. Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease. J Hepatol. 2018;69:1349–56. https://doi.org/10.1016/j.jhep.2018.08.011.CrossRefPubMed

33.

Negi CK, Babica P, Bajard L, et al. Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease. Metabolism. 2022;126:154925. https://doi.org/10.1016/j.metabol.2021.154925.CrossRefPubMed

34.

Mitter SS, Shah SJ, Thomas JD. A Test in Context: E/A and E/e’ to Assess Diastolic Dysfunction and LV Filling Pressure. J Am Coll Cardiol. 2017;69:1451–64. https://doi.org/10.1016/j.jacc.2016.12.037.CrossRefPubMed

35.

Aksu E, Sokmen A, Ispiroglu M, et al. Early cardiac electrical and structural changes in patients with non-obese non-alcoholic fatty liver disease. Kardiologiia. 2021;61:51–8. https://doi.org/10.18087/cardio.2021.5.n1416.CrossRefPubMed

36.

Catena C, Brosolo G, Da Porto A, et al. Association of non-alcoholic fatty liver disease with left ventricular changes in treatment-naive patients with uncomplicated hypertension. Front Cardiovasc Med. 2022;9:1030968. https://doi.org/10.3389/fcvm.2022.1030968.CrossRefPubMedPubMedCentral

37.

Borges-Canha M, Neves JS, Libânio D, et al. Association between nonalcoholic fatty liver disease and cardiac function and structure-a meta-analysis. Endocrine. 2019;66:467–76. https://doi.org/10.1007/s12020-019-02070-0.CrossRefPubMed

38.

Wijarnpreecha K, Lou S, Panjawatanan P, et al. Association between diastolic cardiac dysfunction and nonalcoholic fatty liver disease: A systematic review and meta-analysis. Dig Liver Dis. 2018;50:1166–75. https://doi.org/10.1016/j.dld.2018.09.004.CrossRefPubMed

39.

Lai YH, Su CH, Hung TC, et al. Association of Non-Alcoholic Fatty Liver Disease and Hepatic Fibrosis with Epicardial Adipose Tissue Volume and Atrial Deformation Mechanics in a Large Asian Population Free from Clinical Heart Failure. Diagnostics (Basel). 2022;12:916. https://doi.org/10.3390/diagnostics12040916.CrossRefPubMedPubMedCentral

40.

Yong JN, Ng CH, Lee CW, et al. Non-alcoholic fatty liver disease association with structural heart, systolic and diastolic dysfunction: a meta-analysis. Hepatol Int. 2022;16:269–81. https://doi.org/10.1007/s12072-022-10319-6.CrossRefPubMed

41.

Jung JY, Park SK, Ryoo JH, et al. Effect of non-alcoholic fatty liver disease on left ventricular diastolic function and geometry in the Korean general population. Hepatol Res. 2017;47:522–32. https://doi.org/10.1111/hepr.12770.CrossRefPubMed

42.

Petta S, Argano C, Colomba D, et al. Epicardial fat, cardiac geometry and cardiac function in patients with non-alcoholic fatty liver disease: association with the severity of liver disease. J Hepatol. 2015;62:928–33. https://doi.org/10.1016/j.jhep.2014.11.030.CrossRefPubMed

43.

Zhang Z, Xun Y, Rong S, et al. Loss of immunity-related GTPase GM4951 leads to nonalcoholic fatty liver disease without obesity. Nat Commun. 2022;13:4136. https://doi.org/10.1038/s41467-022-31812-4.CrossRefPubMedPubMedCentral

44.

Chiu LS, Pedley A, Massaro JM, et al. The association of non-alcoholic fatty liver disease and cardiac structure and function-Framingham Heart Study. Liver Int. 2020;40:2445–54. https://doi.org/10.1111/liv.14600.CrossRefPubMedPubMedCentral

45.

VanWagner LB, Wilcox JE, Ning H, et al. Longitudinal Association of Non-Alcoholic Fatty Liver Disease With Changes in Myocardial Structure and Function: The CARDIA Study. J Am Heart Assoc. 2020;9:e014279. https://doi.org/10.1161/jaha.119.014279.CrossRefPubMedPubMedCentral

46.

Dai W, Zhang Z, Zhao S. The Risk of Type 2 Diabetes and Coronary Artery Disease in Non-obese Patients With Non-alcoholic Fatty Liver Disease: A Cohort Study. Front Cardiovasc Med. 2021;8:680664. https://doi.org/10.3389/fcvm.2021.680664.CrossRefPubMedPubMedCentral

47.

Younes R, Govaere O, Petta S, et al. Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?. Gut. 2022;71:382–90. https://doi.org/10.1136/gutjnl-2020-322564.CrossRefPubMed

48.

Sookoian S, Pirola CJ. Systematic review with meta-analysis: the significance of histological disease severity in lean patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2018;47:16–25. https://doi.org/10.1111/apt.14401.CrossRefPubMed

49.

Watt MJ, Miotto PM, De Nardo W, et al. The Liver as an Endocrine Organ-Linking NAFLD and Insulin Resistance. Endocr Rev. 2019;40:1367–93. https://doi.org/10.1210/er.2019-00034.CrossRefPubMed

50.

Portillo-Sanchez P, Bril F, Maximos M, et al. High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels. J Clin Endocrinol Metab. 2015;100:2231–8. https://doi.org/10.1210/jc.2015-1966.CrossRefPubMedPubMedCentral

51.

Feldman A, Eder SK, Felder TK, et al. Clinical and Metabolic Characterization of Lean Caucasian Subjects With Non-alcoholic Fatty Liver. Am J Gastroenterol. 2017;112:102–10. https://doi.org/10.1038/ajg.2016.318.CrossRefPubMed

52.

Boursier J, Mueller O, Barret M, et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology. 2016;63:764–75. https://doi.org/10.1002/hep.28356.CrossRefPubMed

53.

Loomba R, Seguritan V, Li W, et al. Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease. Cell Metab. 2017;25:1054-1062.e1055. https://doi.org/10.1016/j.cmet.2017.04.001.CrossRefPubMedPubMedCentral

54.

Iwaki M, Kessoku T, Ozaki A, et al. Gut microbiota composition associated with hepatic fibrosis in non-obese patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2021;36:2275–84. https://doi.org/10.1111/jgh.15487.CrossRefPubMed

55.

Kalia HS, Gaglio PJ. The Prevalence and Pathobiology of Nonalcoholic Fatty Liver Disease in Patients of Different Races or Ethnicities. Clin Liver Dis. 2016;20:215–24. https://doi.org/10.1016/j.cld.2015.10.005.CrossRefPubMed

56.

Hernaez R, McLean J, Lazo M, et al. Association between variants in or near PNPLA3, GCKR, and PPP1R3B with ultrasound-defined steatosis based on data from the third National Health and Nutrition Examination Survey. Clin Gastroenterol Hepatol. 2013;11:1183-1190.e1182. https://doi.org/10.1016/j.cgh.2013.02.011.CrossRefPubMedPubMedCentral

57.

Sookoian S, Castaño GO, Scian R, et al. Genetic variation in transmembrane 6 superfamily member 2 and the risk of nonalcoholic fatty liver disease and histological disease severity. Hepatology. 2015;61:515–25. https://doi.org/10.1002/hep.27556.CrossRefPubMed

58.

Mancina RM, Dongiovanni P, Petta S, et al. The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent. Gastroenterology. 2016;150:1219-1230.e1216. https://doi.org/10.1053/j.gastro.2016.01.032.CrossRefPubMed

59.

Petersen KF, Dufour S, Hariri A, et al. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N Engl J Med. 2010;362:1082–9. https://doi.org/10.1056/NEJMoa0907295.CrossRefPubMedPubMedCentral

60.

Abul-Husn NS, Cheng X, Li AH, et al. A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease. N Engl J Med. 2018;378:1096–106. https://doi.org/10.1056/NEJMoa1712191.CrossRefPubMedPubMedCentral

61.

Graff M, North KE, Franceschini N, et al. PNPLA3 gene-by-visceral adipose tissue volume interaction and the pathogenesis of fatty liver disease: the NHLBI family heart study. Int J Obes (Lond). 2013;37:432–8. https://doi.org/10.1038/ijo.2012.65.CrossRefPubMed

62.

Wei JL, Leung JC, Loong TC, et al. Prevalence and Severity of Nonalcoholic Fatty Liver Disease in Non-Obese Patients: A Population Study Using Proton-Magnetic Resonance Spectroscopy. Am J Gastroenterol. 2015;110:1306–14. https://doi.org/10.1038/ajg.2015.235. (quiz 1315).CrossRefPubMed

63.

Dongiovanni P, Petta S, Maglio C, et al. Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology. 2015;61:506–14. https://doi.org/10.1002/hep.27490.CrossRefPubMed

64.

Fracanzani AL, Petta S, Lombardi R, et al. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity. Clin Gastroenterol Hepatol. 2017;15:1604-1611.e1601. https://doi.org/10.1016/j.cgh.2017.04.045.CrossRefPubMed

65.

Iwaki M, Kessoku T, Tanaka K, et al. Comparison of long-term prognosis between non-obese and obese patients with non-alcoholic fatty liver disease. JGH Open. 2022;6:696–703. https://doi.org/10.1002/jgh3.12808.CrossRefPubMedPubMedCentral

66.

Francque SM, van der Graaff D, Kwanten WJ. Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications. J Hepatol. 2016;65:425–43. https://doi.org/10.1016/j.jhep.2016.04.005.CrossRefPubMed

67.

Stahl EP, Dhindsa DS, Lee SK, et al. Nonalcoholic Fatty Liver Disease and the Heart: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019;73:948–63. https://doi.org/10.1016/j.jacc.2018.11.050.CrossRefPubMed

68.

Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut. 2020;69:1691–705. https://doi.org/10.1136/gutjnl-2020-320622.CrossRefPubMed

69.

Chang Y, Ryu S, Sung KC, et al. Alcoholic and non-alcoholic fatty liver disease and associations with coronary artery calcification: evidence from the Kangbuk Samsung Health Study. Gut. 2019;68:1667–75. https://doi.org/10.1136/gutjnl-2018-317666.CrossRefPubMed

70.

Ahmed OT, Gidener T, Mara KC, et al. Natural History of Nonalcoholic Fatty Liver Disease With Normal Body Mass Index: A Population-Based Study. Clin Gastroenterol Hepatol. 2021. https://doi.org/10.1016/j.cgh.2021.07.016.CrossRefPubMedPubMedCentral

Title: Correlation between nonalcoholic fatty liver disease and left ventricular diastolic dysfunction in non-obese adults: a cross-sectional study
Authors: Fangyuan Cong
Luying Zhu
Lihua Deng
Qian Xue
Jingtong Wang
Publication date: 01-12-2023
Publisher: BioMed Central
Keyword: Fatty Liver
Published in: BMC Gastroenterology / Issue 1/2023
Electronic ISSN: 1471-230X
DOI: https://doi.org/10.1186/s12876-023-02708-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background and aims

Methods and results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2023

Role of colectomy in the management of appendiceal tumors: a retrospective cohort study

5-year oncological outcomes in left-sided malignant colonic obstruction: stent as bridge to surgery

Risk factors of additional surgery after non-curative endoscopic submucosal dissection for early gastric cancer

The effect of BMI on long-term outcome in patients with rectal cancer and establishment of a nomogram prediction model

Retraction Note: The profile of the key pro-inflammatory cytokines in the serum of patients with CD and their association with the disease severity and activity

Accessory hepatic vein recanalization for Budd-Chiari syndrome: a systematic review and meta-analysis

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage